About The Study: Inferences about clinical impacts based on population-level mean treatment effects may be misleading, since even small between-group differences may reflect clinically important treatment benefits for individual patients. Results of this study suggest that clinical trials should explicitly describe the distributions of Kansas City Cardiomyopathy Questionnaire change at the patient level within treatment groups to support the clinical interpretation of their results.
Corresponding Author: To contact the corresponding author, John Spertus, MD, MPH, email spertusj@umkc.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2024.4470)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the AHA’s Quality of Care and Outcomes Research Early Career Investigator Abstract Award Competition.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.4470?guestAccessKey=fe8933ab-b2a5-4564-918c-b64dc5a29686&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111524
Journal
JAMA Cardiology